ConductScience.org, home

Paper40580997

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.

Tsimberidou AM and 13 others. Oncologist, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. Papers, record 40580997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40580997

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.
PubMed
Journal
Oncologist
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase I
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.36, provisional
iCite
Revised in PubMed
2025-07-29
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tsimberidou AMApostolia Mhttps://orcid.org/0000-0003-2713-233X
2Dayyani FFarshidhttps://orcid.org/0000-0002-4970-5189
3Sommerhalder DDavid
4Vandross ALAndrae L
5Pelster MSMeredith S
6Henry JTJason T
7Perez CACesar A
8Chakraborty AAbhijit
9Baysal MAMehmet Ahttps://orcid.org/0000-0002-8446-6531
10Chandhasin CChandtip
11Dai YYiyun
12Tu SShirley
13King IIvan
14Perabo FFrank

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Jumonji Domain-Containing Histone DemethylasesMajor topic
Humans
Male
Middle Aged
Female
Aged
Adult
Maximum Tolerated Dose

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER
CLIN2-14232California Institute for Regenerative MedicinePubMedPubMed
University of Texas MD Anderson Cancer CenterPubMedPubMed
Tachyon Therapeutics, IncPubMedPubMed
NIH HHSUnited StatesPubMedPubMed
R03AG014232NIHNIH RePORTER

Download CSV of grants

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127266524Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.EMBO J2016https://conductscience.org/library/papers/27266524PubMed
225770186Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway.Biol Open2015https://conductscience.org/library/papers/25770186PubMed
323644528KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.Cancer Res2013https://conductscience.org/library/papers/23644528PubMed
427630312Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.Anticancer Res2016https://conductscience.org/library/papers/27630312PubMed
530967636JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.Oncogene2019https://conductscience.org/library/papers/30967636PubMed
631766290Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.Cancers (Basel)2019https://conductscience.org/library/papers/31766290PubMed
728883001KDM4 Inhibition Targets Breast Cancer Stem-like Cells.Cancer Res2017https://conductscience.org/library/papers/28883001PubMed
827506941KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.Oncotarget2016https://conductscience.org/library/papers/27506941PubMed
919097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1017555712Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.Biochem Biophys Res Commun2007https://conductscience.org/library/papers/17555712PubMed
1122948256Oncogenic features of the JMJD2A histone demethylase in breast cancer.Int J Oncol2012https://conductscience.org/library/papers/22948256PubMed
1223603248Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.Cancer Lett2013https://conductscience.org/library/papers/23603248PubMed
1328835804Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.ACS Med Chem Lett2017https://conductscience.org/library/papers/28835804PubMed
1419696013The histone demethylase JMJD2C is stage-specifically expressed in preimplantation mouse embryos and is required for embryonic development.Biol Reprod2010https://conductscience.org/library/papers/19696013PubMed
1517218267Dynamic regulation of histone lysine methylation by demethylases.Mol Cell2007https://conductscience.org/library/papers/17218267PubMed
1633558705USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription.Cell Death Differ2021https://conductscience.org/library/papers/33558705PubMed
1727257215Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.Genes Dev2016https://conductscience.org/library/papers/27257215PubMed
1837067993TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.Anticancer Drugs2023https://conductscience.org/library/papers/37067993PubMed
1922133676Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.Biochem Biophys Res Commun2011https://conductscience.org/library/papers/22133676PubMed
2031665047JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway.J Exp Clin Cancer Res2019https://conductscience.org/library/papers/31665047PubMed

See all 21 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42903410Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis.Front Immunol2026https://conductscience.org/library/papers/42903410PubMed
42888460Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies.Biomark Res2026https://conductscience.org/library/papers/42888460PubMed
42839081Context matters for drug targeting.Nat Chem Biol2026https://conductscience.org/library/papers/42839081PubMed
42783444Therapeutic Vulnerabilities of the Key Genetic Drivers in Leiomyosarcoma.Med Sci (Basel)2026https://conductscience.org/library/papers/42783444PubMed
42449712Overcoming Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma (HNSCC): The Role of Histone Methyltransferase and Demethylase Inhibitors.Cancers (Basel)2026https://conductscience.org/library/papers/42449712PubMed
42325777KDM4D enhances radiosensitivity in esophageal squamous cell carcinoma through the SRBD1/RPL11/c-Myc/WIP1/CHK1 axis.Am J Transl Res2026https://conductscience.org/library/papers/42325777PubMed
41857315The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.Mol Biomed2026https://conductscience.org/library/papers/41857315PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40580997

GET https://conductscience.org/api/papers/v1/40580997/references?page=2